Academic Content and Language Evaluation of This Article
CrossCheck and Google Search of This Article
Academic Rules and Norms of This Article
Supplementary Materials of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (8259)
All Articles published online
|
Publishing Process of This Article
|
Feb 27, 2023 (publication date) through May 6, 2025
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Hepatology
ISSN
1948-5182
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Kram M. Galectin-3 inhibition as a potential therapeutic target in non-alcoholic steatohepatitis liver fibrosis. World J Hepatol 2023; 15(2): 201-207 [PMID: 36926236 DOI: 10.4254/wjh.v15.i2.201] |
|---|---|
| URL: | https://www.wjgnet.com/1948-5182/full/v15/i2/201.htm |
| Number | Citing Articles |
| 1 |
Shima Mimura, Asahiro Morishita, Kyoko Oura, Kei Takuma, Mai Nakahara, Tomoko Tadokoro, Koji Fujita, Joji Tani, Hideki Kobara. Galectins and Liver Diseases. International Journal of Molecular Sciences 2025; 26(2): 790 doi: 10.3390/ijms26020790
|
| 2 |
Anna Lisa Cammarota, Antonia Falco, Anna Basile, Carlo Molino, Massimiliano Chetta, Gianni D’Angelo, Liberato Marzullo, Margot De Marco, Maria Caterina Turco, Alessandra Rosati. Pancreatic Cancer-Secreted Proteins: Targeting Their Functions in Tumor Microenvironment. Cancers 2023; 15(19): 4825 doi: 10.3390/cancers15194825
|
| 3 |
Huseyin Ali Ozturk, Hilmi Erdem Sumbul. Liver stiffness and serum galectin 3 level significantly increases in patients with prediabetes: a fibroscan study. PeerJ 2025; 13: e19377 doi: 10.7717/peerj.19377
|
| 4 |
Ming-Shyan Lin, Ya-Chi Tu, Yu-Sheng Lin, Meng-Hung Lin, Chun-Liang Lin, Ming-Horng Tsai, Yung-Yu Hsieh, Tien-Hsing Chen, Mei-Yen Chen, Chung-Sheng Shi. Association between galectin-3 and hepatosteatosis in a community-based cross-sectional study. Therapeutic Advances in Chronic Disease 2024; 15 doi: 10.1177/20406223241302719
|
| 5 |
Shunsuke Miyauchi, Miki Kawada-Matsuo, Hisako Furusho, Hiromi Nishi, Ayako Nakajima, Pham Trong Phat, Fumie Shiba, Masae Kitagawa, Kazuhisa Ouhara, Noboru Oda, Takehito Tokuyama, Yousaku Okubo, Sho Okamura, Taiichi Takasaki, Shinya Takahashi, Toru Hiyama, Hiroyuki Kawaguchi, Hitoshi Komatsuzawa, Mutsumi Miyauchi, Yukiko Nakano.
Atrial Translocation of
Porphyromonas gingivalis
Exacerbates Atrial Fibrosis and Atrial Fibrillation
. Circulation 2025; doi: 10.1161/CIRCULATIONAHA.124.071310
|
| 6 |
Angeliki Katsarou, Georgios Tsioulos, Eva Kassi, Antonios Chatzigeorgiou. Current and experimental pharmacotherapy for the management of non-alcoholic fatty liver disease. Hormones 2024; 23(4): 621 doi: 10.1007/s42000-024-00588-1
|
| 7 |
Yasmin Mohtasham Kia, Alessandro Cannavo, Pegah Bahiraie, Sanam Alilou, Behrad Saeedian, Nastaran Babajani, Elina Ghondaghsaz, Amirmohammad Khalaji, Amir Hossein Behnoush, Sowjanya Thatikonda. Insights into the Role of Galectin-3 as a Diagnostic and Prognostic Biomarker of Atrial Fibrillation. Disease Markers 2023; 2023: 1 doi: 10.1155/2023/2097012
|
| 8 |
Michail Kokkorakis, Emir Muzurović, Špela Volčanšek, Marlene Chakhtoura, Michael A. Hill, Dimitri P. Mikhailidis, Christos S. Mantzoros. Steatotic Liver Disease: Pathophysiology and Emerging Pharmacotherapies. Pharmacological Reviews 2024; 76(3): 454 doi: 10.1124/pharmrev.123.001087
|
| 9 |
Shifang Tang, Jürgen Borlak. Genomics of human NAFLD: Lack of data reproducibility and high interpatient variability in drug target expression as major causes of drug failures. Hepatology 2024; 80(4): 901 doi: 10.1097/HEP.0000000000000780
|
| 10 |
Praveenkumar Shetty, Pavan K. Jayaswamy, Prakash Patil, M. Vijaykrishnaraj, Jamboor K. Vishwanatha, Sukanya Shetty. Cardiometabolic Diseases. 2025; : 159 doi: 10.1016/B978-0-323-95469-3.00029-2
|
| 11 |
Qian Jiang, Qijin Zhao, Pingping Li. Galectin-3 in metabolic disorders: mechanisms and therapeutic potential. Trends in Molecular Medicine 2024; doi: 10.1016/j.molmed.2024.11.006
|
| 12 |
Arun George Devasia, Adaikalavan Ramasamy, Chen Huei Leo. Current Therapeutic Landscape for Metabolic Dysfunction-Associated Steatohepatitis. International Journal of Molecular Sciences 2025; 26(4): 1778 doi: 10.3390/ijms26041778
|
| 13 |
Paolo Comeglio, Giulia Guarnieri, Sandra Filippi, Ilaria Cellai, Gabriele Acciai, Ian Holyer, Fredrik Zetterberg, Hakon Leffler, Barbro Kahl-Knutson, Erica Sarchielli, Annamaria Morelli, Mario Maggi, Robert J. Slack, Linda Vignozzi. The galectin-3 inhibitor selvigaltin reduces liver inflammation and fibrosis in a high fat diet rabbit model of metabolic-associated steatohepatitis. Frontiers in Pharmacology 2024; 15 doi: 10.3389/fphar.2024.1430109
|
| 14 |
Ikki Sakuma, Rafael C. Gaspar, Ali R. Nasiri, Sylvie Dufour, Mario Kahn, Jie Zheng, Traci E. LaMoia, Mateus T. Guerra, Yuki Taki, Yusuke Kawashima, Dean Yimlamai, Mark Perelis, Daniel F. Vatner, Kitt Falk Petersen, Maximilian Huttasch, Birgit Knebel, Sabine Kahl, Michael Roden, Varman T. Samuel, Tomoaki Tanaka, Gerald I. Shulman. Liver lipid droplet cholesterol content is a key determinant of metabolic dysfunction–associated steatohepatitis. Proceedings of the National Academy of Sciences 2025; 122(18) doi: 10.1073/pnas.2502978122
|
| 15 |
Jorge Arnold, Francisco Idalsoaga, Luis Antonio Díaz, Daniel Cabrera, Francisco Barrera, Juan Pablo Arab, Marco Arrese. Emerging Drug Therapies for Metabolic Dysfunction-Associated Steatotic Liver Disease: A Glimpse into the Horizon. Current Hepatology Reports 2024; 23(1): 204 doi: 10.1007/s11901-023-00629-0
|
| 16 |
Eda Ates, Hien Thi My Ong, Seung-Min Yu, Ji-Hoon Kim, Min-Jung Kang. Comparative Analysis of the Total Proteome in Nonalcoholic Steatohepatitis: Identification of Potential Biomarkers. Molecular & Cellular Proteomics 2025; 24(3): 100921 doi: 10.1016/j.mcpro.2025.100921
|
| 17 |
Mohammadjavad Sotoudeheian. Galectin-3 and Severity of Liver Fibrosis in Metabolic
Dysfunction-Associated Fatty Liver Disease. Protein & Peptide Letters 2024; 31(4): 290 doi: 10.2174/0109298665301698240404061300
|